Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | MMP12 | P39900 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110361 | 0.92 | MMP12 (0.32) | ACLYPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1110321 | 0.91 | TSHR (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1110399 | 0.91 | MMP12 (0.37) | ACLYMMP2MMP9MMP8MMP12 | |
| SCHEMBL1110234 | 0.91 | MMP12 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1110507 | 0.90 | ITGA4 (0.30) | — | |
| SCHEMBL1110521 | 0.89 | KMT2A (0.34) | — | |
| SCHEMBL1110203 | 0.86 | ACLY (0.32) | ACLYPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1319326 | 0.85 | ALDH1A1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1110313 | 0.83 | ALDH1A1 (0.39) | ACLY | |
| SCHEMBL1110157 | 0.82 | MAPK1 (0.37) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | ACLY 1173/4885PSEN1 2282/4885PSEN2 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.